Showing results (2641-2650 of 2,815) with videos related to

Sort By:
Pageof 282
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaC N Owen, X Bai, T Quah, et al.
Nature Communications|November 21, 2025
Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric central nervous system tumorsRyan J Corbett, Rebecca S Kaufman, Shelly W McQuaid, et al.
Nature Communications|January 2, 2025
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis productAvanish Mishra, Shih-Bo Huang, Taronish Dubash, et al.
Nature Biotechnology|January 9, 2018
Functional interrogation and mining of natively paired human VH:VL antibody repertoiresBo Wang, Brandon J DeKosky, Morgan R Timm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2024
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis productAvanish Mishra, Shih-Bo Huang, Taronish Dubash, et al.
Nature Communications|June 24, 2026
Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistanceSamuel J Wright, Izabella Zamora, Milan Parikh, et al.
The Oncologist|March 3, 2021
Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018Gabriel E Molina, Leyre Zubiri, Justine V Cohen, et al.
JAMA Oncology|April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical TrialGuo Chen, Jennifer L McQuade, David J Panka, et al.
Lancet (London, England)|December 8, 2009
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, B Romanowski, P Colares de Borba, et al.
Pageof 282